AU2013289854B2 - Risk stratification in influenza - Google Patents

Risk stratification in influenza Download PDF

Info

Publication number
AU2013289854B2
AU2013289854B2 AU2013289854A AU2013289854A AU2013289854B2 AU 2013289854 B2 AU2013289854 B2 AU 2013289854B2 AU 2013289854 A AU2013289854 A AU 2013289854A AU 2013289854 A AU2013289854 A AU 2013289854A AU 2013289854 B2 AU2013289854 B2 AU 2013289854B2
Authority
AU
Australia
Prior art keywords
level
patient
gene product
seq
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013289854A
Other languages
English (en)
Other versions
AU2013289854A2 (en
AU2013289854A1 (en
Inventor
Anthony MCLEAN
Grant Peter Parnell
Maryam SHOJAEI
Benjamin Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEPEAN BLUE MOUNTAINS LOCAL HEALTH DISTRICT
Original Assignee
NEPEAN BLUE MOUNTAINS LOCAL HEALTH DISTR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902954A external-priority patent/AU2012902954A0/en
Application filed by NEPEAN BLUE MOUNTAINS LOCAL HEALTH DISTR filed Critical NEPEAN BLUE MOUNTAINS LOCAL HEALTH DISTR
Priority to AU2013289854A priority Critical patent/AU2013289854B2/en
Publication of AU2013289854A1 publication Critical patent/AU2013289854A1/en
Publication of AU2013289854A2 publication Critical patent/AU2013289854A2/en
Application granted granted Critical
Publication of AU2013289854B2 publication Critical patent/AU2013289854B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2013289854A 2012-07-10 2013-07-10 Risk stratification in influenza Ceased AU2013289854B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013289854A AU2013289854B2 (en) 2012-07-10 2013-07-10 Risk stratification in influenza

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012902954A AU2012902954A0 (en) 2012-07-10 Risk stratification in influenza
AU2012902954 2012-07-10
AU2013289854A AU2013289854B2 (en) 2012-07-10 2013-07-10 Risk stratification in influenza
PCT/AU2013/000765 WO2014008545A1 (en) 2012-07-10 2013-07-10 Risk stratification in influenza

Publications (3)

Publication Number Publication Date
AU2013289854A1 AU2013289854A1 (en) 2015-01-22
AU2013289854A2 AU2013289854A2 (en) 2015-02-26
AU2013289854B2 true AU2013289854B2 (en) 2016-03-24

Family

ID=49915252

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013289854A Ceased AU2013289854B2 (en) 2012-07-10 2013-07-10 Risk stratification in influenza

Country Status (10)

Country Link
US (2) US10036075B2 (https=)
EP (1) EP2872891B1 (https=)
JP (1) JP6097388B2 (https=)
KR (1) KR20150040289A (https=)
CN (1) CN104769430B (https=)
AU (1) AU2013289854B2 (https=)
BR (1) BR112015000685A2 (https=)
CA (1) CA2877400A1 (https=)
DK (1) DK2872891T3 (https=)
WO (1) WO2014008545A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3367099B1 (en) 2012-02-09 2021-05-26 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2015103664A1 (en) * 2014-01-09 2015-07-16 Nepean Blue Montains Local Health District Risk stratification in influenza
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
EP3146974A1 (en) 2015-09-25 2017-03-29 Universite Claude Bernard - Lyon 1 Biomarkers for early determination of severity of influenza related disease
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS
IL287757B (en) 2016-03-03 2022-07-01 Memed Diagnostics Ltd Analyzing rna for diagnosing infection type
EP3482201B1 (en) 2016-07-10 2022-12-14 Memed Diagnostics Ltd. Early diagnosis of infections
EP3482200B1 (en) 2016-07-10 2022-05-04 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US12344893B2 (en) 2018-06-05 2025-07-01 Washington University Nasal genes used to identify, characterize, and diagnose viral respiratory infections
JP7846017B2 (ja) * 2020-04-09 2026-04-14 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 気道感染症の診断のためのバイオマーカー

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208496A1 (en) * 2002-08-06 2005-09-22 Genox Research, Inc. Methods of testing for bronchial asthma or chronic obstructive pulmonary disease
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US20120114661A1 (en) * 2009-05-26 2012-05-10 Ginsburg Geoffrey S Methods of identifying infectious disease and assays for identifying infectious disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792626A (en) * 1996-09-18 1998-08-11 Incyte Pharmaceuticals, Inc. Human interferon-inducible protein
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US7214498B2 (en) * 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
WO2005068664A2 (en) * 2004-01-09 2005-07-28 The Regents Of The University Of California Cell-type-specific patterns of gene expression
WO2007034280A2 (en) * 2005-09-19 2007-03-29 Moshe Amihood Blay Composition and method for prevention of influenza
AU2007286915B2 (en) * 2006-08-11 2014-05-15 Baylor Research Institute Gene expression signatures in blood leukocytes permit differential diagnosis of acute infections
WO2009148150A1 (ja) * 2008-06-06 2009-12-10 国立大学法人富山大学 インフルエンザウィルス検出用デバイス
WO2010076788A2 (en) * 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
EP2451476A4 (en) 2009-07-06 2013-07-03 Alnylam Pharmaceuticals Inc BIOTRAITEMENT BASED ON CELLS
US20120214705A1 (en) * 2009-09-28 2012-08-23 The Regents Of The University Of California Office of Technology, Beta-defensin 2 genetic variation predicts h. pylori susceptibility
EP2751286A1 (en) * 2011-09-04 2014-07-09 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Prognostic methods and compositions for predicting interferon treatment eficacy in a subject

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208496A1 (en) * 2002-08-06 2005-09-22 Genox Research, Inc. Methods of testing for bronchial asthma or chronic obstructive pulmonary disease
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US20120114661A1 (en) * 2009-05-26 2012-05-10 Ginsburg Geoffrey S Methods of identifying infectious disease and assays for identifying infectious disease

Also Published As

Publication number Publication date
KR20150040289A (ko) 2015-04-14
EP2872891A1 (en) 2015-05-20
CA2877400A1 (en) 2014-01-16
US20150322538A1 (en) 2015-11-12
WO2014008545A1 (en) 2014-01-16
CN104769430A (zh) 2015-07-08
EP2872891A4 (en) 2016-01-20
CN104769430B (zh) 2018-12-14
JP6097388B2 (ja) 2017-03-15
BR112015000685A2 (pt) 2017-11-28
US10036075B2 (en) 2018-07-31
JP2015530868A (ja) 2015-10-29
AU2013289854A2 (en) 2015-02-26
DK2872891T3 (da) 2019-05-13
AU2013289854A1 (en) 2015-01-22
EP2872891B1 (en) 2019-03-13
US20180298455A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
AU2013289854B2 (en) Risk stratification in influenza
JP5555626B2 (ja) 多発性硬化症、アルツハイマー病およびパーキンソン病を処置するためのケモカインのｉｖｉｇ調節
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
US20190367984A1 (en) Methods for predicting response to anti-tnf therapy
JP2016526888A (ja) 敗血症バイオマーカー及びそれらの使用
JP2010535825A5 (https=)
ES3052973T3 (en) Prediction of therapeutic response in inflammatory conditions
JP2013526845A (ja) サイトカイン標的薬（ＣｙＴＤ）に対する、炎症性疾患に罹患している対象の初期応答または非応答を予測する遺伝子および遺伝子の組み合わせ
EP2074230A2 (en) Compositions and methods for treating and diagnosing irritable bowel syndrome
US20230003719A1 (en) Materials and methods for inflammatory molecular markers
US20230014092A1 (en) Materials and methods for monitoring inflammation
KR101620274B1 (ko) 비만의 진단용 조성물 및 이의 용도
WO2011065168A1 (ja) 関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
US20140221235A1 (en) Biomarker algorithm for determining the time of stroke symptom onset and method
WO2015103664A1 (en) Risk stratification in influenza
WO2011041725A2 (en) Schizophrenia treatment response biomarkers
Salem et al. Association of plasma microRNAs with COVID-19 severity and outcome
Zhao et al. Systematic and integrated analysis of tRNA-derived small RNAs reveals novel potential pathogenesis targets of sarcoidosis
Fadhil et al. Nuclear factor-kappa B gene polymorphism and interleukin-8 in Iraqi population with severe chronic periodontitis
EP4230749A1 (en) In vitro method for predicting a risk of post-chikungunya chronic inflammatory joint disease
US20250297314A1 (en) Determining the risk of death of a subject infected with a respiratory virus by measuring the expression level of the cd74 gene
RU2749248C1 (ru) Способ прогнозирования эффективности лечения ревматоидного артрита препаратом олокизумаб с использованием эпигенетических маркеров
Venkatesan et al. Exosomal MicroRNA from Blood Plasma as a Predictive Biomarker for Bleeding Tendency in Dengue Infection
WO2025041146A1 (en) Markers of resistance and systemic inflammation and uses thereof
US20250298015A1 (en) Diagnostic method of detecting inflammation biomarker(s)

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JAN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired